Immunotherapy in NSCLC

سال انتشار: 1398
نوع سند: مقاله کنفرانسی
زبان: انگلیسی
مشاهده: 398

نسخه کامل این مقاله ارائه نشده است و در دسترس نمی باشد

استخراج به نرم افزارهای پژوهشی:

لینک ثابت به این مقاله:

شناسه ملی سند علمی:

ISMOH18_003

تاریخ نمایه سازی: 8 بهمن 1398

چکیده مقاله:

Lung cancer is the leading case of cancer related mortality in the world. More than 80 precent of lung cancer are classified as non small cell lung cancer (NSCLC). Cancer immunotherapy aims to augment recognition of cancer as foreign, stimulate immune responsiveness and relieve inhibition of the immune system that allows tolerane of tumor survival and growth.Immune check point inhibitors targeting the programmed death receptor (PD-1) axis have become integrated into the clinical approach for management of non small cell lung cancer (NSCLC) . for patient who have not received systemic therapy for advanced NSCLC and lack contratndi-cation to immunotherapy (an active) Auto-immuno condition requiring lmmunosuppressive treatment, we assess tumor progammed death ligand-1.For patient with NSCLC that lacks a driven mutation and has either less than 50 percent of tumor cell staining for PD-L1 or unknown PD-L1 espression, we suggest the combination of pemhrolizumab with pemetrexed and either Carboplatin Or Cisplatin rather than platinum – doublet chemotherapy alone.Multiple immune check point Inhibitors are currently in clinical development either as monotherapy or in combination with other immunotherapies, chemotherapy, targeted therapy or radition, results with further define the role of immune check point Inhibitors in the treatment of NSCLC. For patient treated with a PD-1 axis inhibitor, we suggest continued treatment until progression or unacceptable toxicity occurs.

نویسندگان

Babak Salimi

Medical Oncologist and Hematologist Masih Daneshvari Hospital, Shahid Beheshti Medical University